Our aim was to assess the in vitro short-term effects and after 6 and 12 months of IFN-β treatment on the circulating sIFNAR2 levels and on the gene expression of the different IFNAR2 splice variants in MS patients, as well as their relation with the therapeutic response to IFN-β. This evidence concerns the gene IFNAR2 and myeloid sarcoma.